

# Tina Vilsboll

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/2613107/tina-vilsboll-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

274  
papers

15,996  
citations

56  
h-index

122  
g-index

314  
ext. papers

19,011  
ext. citations

6.1  
avg, IF

6.7  
L-index

#	Paper	IF	Citations
274	Gastric Aspiration Improves Postprandial Glucose Tolerance Without Causing a Compensatory Increase in Appetite and Food Intake.. <i>Obesity Surgery</i> , <b>2022</b> , 32, 1385	3.7	
273	Glucose-dependent insulintropic polypeptide induces lipolysis during stable basal insulin substitution and hyperglycaemia in men with type 1 diabetes: A randomized, double-blind, placebo-controlled, crossover clinical trial. <i>Diabetes, Obesity and Metabolism</i> , <b>2022</b> , 24, 142-147	6.7	0
272	LEAP2 reduces postprandial glucose excursions and food intake in healthy men.. <i>Cell Reports Medicine</i> , <b>2022</b> , 3, 100582	18	3
271	Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes.. <i>Cardiovascular Diabetology</i> , <b>2022</b> , 21, 50	8.7	1
270	Transforming Motivation for Exercise in a Safe and Kind Environment—A Qualitative Study of Experiences among Individuals with Type 2 Diabetes. <i>International Journal of Environmental Research and Public Health</i> , <b>2022</b> , 19, 6091	4.6	0
269	Effectiveness and acceptability of a pragmatic exercise intervention for patients with type 2 diabetes in specialized care.. <i>Diabetes Research and Clinical Practice</i> , <b>2021</b> , 183, 109176	7.4	1
268	Arginine-vasopressin mediates counter-regulatory glucagon release and is diminished in type 1 diabetes. <i>ELife</i> , <b>2021</b> , 10,	8.9	3
267	The role of GLP-1 in the postprandial effects of acarbose in type 2 diabetes. <i>European Journal of Endocrinology</i> , <b>2021</b> , 184, 383-394	6.5	6
266	In patients with controlled acromegaly, indices of glucose homeostasis correlate with IGF-1 levels rather than with type of treatment. <i>Clinical Endocrinology</i> , <b>2021</b> , 95, 65-73	3.4	0
265	The Danish comorbidity in liver transplant recipients study (DACOLT): a non-interventional prospective observational cohort study. <i>BMC Gastroenterology</i> , <b>2021</b> , 21, 145	3	
264	Response to Letter to the Editor from McKee and McGill: "Glycemic Control and Variability of Diabetes Secondary to Total Pancreatectomy Assessed by Continuous Glucose Monitoring". <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2021</b> , 106, e4307-e4308	5.6	
263	Expression of Cholecystokinin and its Receptors in the Intestinal Tract of Type 2 Diabetes Patients and Healthy Controls. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2021</b> , 106, 2164-2170	5.6	3
262	Pancreatic polypeptide: A potential biomarker of glucose-dependent insulintropic polypeptide receptor activation in vivo. <i>Diabetic Medicine</i> , <b>2021</b> , 38, e14592	3.5	0
261	A Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes. <i>Drugs</i> , <b>2021</b> , 81, 1003-1030	12.1	7
260	Acute hypoglycemia and risk of cardiac arrhythmias in insulin-treated type 2 diabetes and controls. <i>European Journal of Endocrinology</i> , <b>2021</b> , 185, 343-353	6.5	2
259	Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 2058-2066	6.7	6
258	Metabolic effects of 1-week binge drinking and fast food intake during Roskilde Festival in young healthy male adults. <i>European Journal of Endocrinology</i> , <b>2021</b> , 185, 23-32	6.5	0

257	Effects of endogenous GIP in patients with type 2 diabetes. <i>European Journal of Endocrinology</i> , <b>2021</b> , 185, 33-45	6.5	4
256	Prognostic Value of Early Systolic Lengthening by Strain Imaging in Type 2 Diabetes. <i>Journal of the American Society of Echocardiography</i> , <b>2021</b> , 34, 127-135	5.8	2
255	Switching between GLP-1 receptor agonists in clinical practice: Expert consensus and practical guidance. <i>International Journal of Clinical Practice</i> , <b>2021</b> , 75, e13731	2.9	11
254	Glycemic Control and Variability of Diabetes Secondary to Total Pancreatectomy Assessed by Continuous Glucose Monitoring. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2021</b> , 106, 168-173	5.6	6
253	Identification and Metabolic Profiling of a Novel Human Gut-derived LEAP2 Fragment. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2021</b> , 106, e966-e981	5.6	11
252	An overview of obesity mechanisms in humans: Endocrine regulation of food intake, eating behaviour and common determinants of body weight. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23 Suppl 1, 17-35	6.7	4
251	Protocol for a randomised, double-blinded, placebo-controlled, double-dummy 6-week clinical trial comparing the treatment effects of the glucagon-like peptide 1 receptor agonist liraglutide versus the bile acid sequestrant colesevelam on bile acid malabsorption. <i>BMJ Open</i> , <b>2021</b> , 11, e044711	3	0
250	Liraglutide does not change bone turnover in clozapine- and olanzapine-treated schizophrenia overweight patients with prediabetes - randomized controlled trial. <i>Psychiatry Research</i> , <b>2021</b> , 296, 113670	9.8	1
249	Glucagonostatic Potency of GLP-1 in Patients With Type 2 Diabetes, Patients With Type 1 Diabetes, and Healthy Control Subjects. <i>Diabetes</i> , <b>2021</b> , 70, 1347-1356	0.9	2
248	How glucagon-like peptide 1 receptor agonists work. <i>Endocrine Connections</i> , <b>2021</b> , 10, R200-R212	3.5	4
247	The effect of 6-day subcutaneous glucose-dependent insulinotropic polypeptide infusion on time in glycaemic range in patients with type 1 diabetes: a randomised, double-blind, placebo-controlled crossover trial. <i>Diabetologia</i> , <b>2021</b> , 64, 2425-2431	10.3	0
246	Once-weekly subcutaneous semaglutide treatment for persons with type 2 diabetes: Real-world data from a diabetes out-patient clinic. <i>Diabetic Medicine</i> , <b>2021</b> , 38, e14655	3.5	5
245	Hepatic microbiome in healthy lean and obese humans. <i>JHEP Reports</i> , <b>2021</b> , 3, 100299	10.3	3
244	Understanding the place for GLP-1RA therapy: Translating guidelines for treatment of type 2 diabetes into everyday clinical practice and patient selection. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23 Suppl 3, 40-52	6.7	4
243	Associations of hypoglycemia, glycemic variability and risk of cardiac arrhythmias in insulin-treated patients with type 2 diabetes: a prospective, observational study. <i>Cardiovascular Diabetology</i> , <b>2021</b> , 20, 241	8.7	3
242	Gut Mucosal Gene Expression and Metabolic Changes After Roux-en-Y Gastric Bypass Surgery. <i>Obesity</i> , <b>2020</b> , 28, 2163-2174	8	2
241	The GLP-1 receptor agonist lixisenatide reduces postprandial glucose in patients with diabetes secondary to total pancreatectomy: a randomised, placebo-controlled, double-blinded crossover trial. <i>Diabetologia</i> , <b>2020</b> , 63, 1285-1298	10.3	2
240	The effect of acute intragastric vs. intravenous alcohol administration on inflammation markers, blood lipids and gallbladder motility in healthy men. <i>Alcohol</i> , <b>2020</b> , 87, 29-37	2.7	1

239	Differential time responses in inflammatory and oxidative stress markers after a marathon: An observational study. <i>Journal of Sports Sciences</i> , <b>2020</b> , 38, 2080-2091	3.6	11
238	Hypoglycaemia and cardiac arrhythmias in diabetes. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , <b>2020</b> , 11, 2042018820911803	4.5	12
237	Effect of short-acting exenatide administered three times daily on markers of cardiovascular disease in type 1 diabetes: A randomized double-blind placebo-controlled trial. <i>Diabetes, Obesity and Metabolism</i> , <b>2020</b> , 22, 1639-1647	6.7	1
236	GIP and GLP-1 Potentiate Sulfonylurea-Induced Insulin Secretion in Hepatocyte Nuclear Factor 1 $\alpha$ Mutation Carriers. <i>Diabetes</i> , <b>2020</b> , 69, 1989-2002	0.9	7
235	Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , <b>2020</b> , 8, 313-324	18.1	18
234	Glucagon-like peptide-1 receptor regulation of basal dopamine transporter activity is species-dependent. <i>Neurochemistry International</i> , <b>2020</b> , 138, 104772	4.4	5
233	GIP and GLP-1 Receptor Antagonism During a Meal in Healthy Individuals. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2020</b> , 105,	5.6	18
232	No Acute Effects of Exogenous Glucose-Dependent Insulinotropic Polypeptide on Energy Intake, Appetite, or Energy Expenditure When Added to Treatment With a Long-Acting Glucagon-Like Peptide 1 Receptor Agonist in Men With Type 2 Diabetes. <i>Diabetes Care</i> , <b>2020</b> , 43, 588-596	14.6	18
231	Glucagon Resistance at the Level of Amino Acid Turnover in Obese Subjects With Hepatic Steatosis. <i>Diabetes</i> , <b>2020</b> , 69, 1090-1099	0.9	15
230	Efficacy and safety of dapagliflozin plus saxagliptin versus insulin glargine over 52 weeks as add-on to metformin with or without sulphonylurea in patients with type 2 diabetes: A randomized, parallel-design, open-label, Phase 3 trial. <i>Diabetes, Obesity and Metabolism</i> , <b>2020</b> , 22, 957-968	6.7	1
229	Clinical Considerations When Initiating and Titrating Insulin Degludec/Liraglutide (IDegLira) in People with Type 2 Diabetes. <i>Drugs</i> , <b>2020</b> , 80, 147-165	12.1	6
228	Semaglutide improves health-related quality of life versus placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (SUSTAIN 6). <i>Diabetes, Obesity and Metabolism</i> , <b>2020</b> , 22, 1339-1347	6.7	8
227	Secretion of parathyroid hormone may be coupled to insulin secretion in humans. <i>Endocrine Connections</i> , <b>2020</b> , 9, 747-754	3.5	1
226	89-LB: The Effect of GIP on Plasma Glucose in a Setting of Prandial Insulin Overdose and Physical Activity after Meal Intake in Patients with Type 1 Diabetes. <i>Diabetes</i> , <b>2020</b> , 69, 89-LB	0.9	2
225	350-OR: A Novel Long-Acting GLP-1 Agonist (GL0034) Demonstrates Remarkable Efficacy on HbA1c, Weight Loss, and Triglycerides in a Model of Type 2 Diabetes, the db/db Mouse. <i>Diabetes</i> , <b>2020</b> , 69, 350-OR	0.9	
224	2187-PUB: Identifying Risk Predictors for Gastrointestinal Adverse Events with Once-Weekly Semaglutide. <i>Diabetes</i> , <b>2020</b> , 69, 2187-PUB	0.9	
223	No detectable effect of a type 2 diabetes-associated TCF7L2 genotype on the incretin effect. <i>Endocrine Connections</i> , <b>2020</b> , 9, 1221-1232	3.5	2
222	Proinflammatory biomarkers are associated with prediabetes in patients with schizophrenia. <i>CNS Spectrums</i> , <b>2020</b> , 1-8	1.8	

221	Glucagon-Like Peptide 2 Inhibits Postprandial Gallbladder Emptying in Man: A Randomized, Double-Blinded, Crossover Study. <i>Clinical and Translational Gastroenterology</i> , <b>2020</b> , 11, e00257	4.2	1
220	Experience of family function, family involvement, and self-management in adult patients with type 2 diabetes: A thematic analysis. <i>Journal of Advanced Nursing</i> , <b>2020</b> , 76, 621-631	3.1	3
219	GIP $\beta$ involvement in the pathophysiology of type 2 diabetes. <i>Peptides</i> , <b>2020</b> , 125, 170178	3.8	7
218	Glucose-Dependent Insulinotropic Polypeptide Is a Pancreatic Polypeptide Secretagogue in Humans. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2020</b> , 105,	5.6	2
217	GIP $\beta$ effect on bone metabolism is reduced by the selective GIP receptor antagonist GIP(3-30)NH $_2$ . <i>Bone</i> , <b>2020</b> , 130, 115079	4.7	11
216	Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk. <i>Diabetes, Obesity and Metabolism</i> , <b>2020</b> , 22, 442-451	6.7	44
215	Effects of Gender-Affirming Hormone Therapy on Insulin Sensitivity and Incretin Responses in Transgender People. <i>Diabetes Care</i> , <b>2020</b> , 43, 411-417	14.6	21
214	Leptin Serum Levels are Associated With GLP-1 Receptor Agonist-Mediated Effects on Glucose Metabolism in Clozapine- or Olanzapine-Treated, Prediabetic, Schizophrenia Patients. <i>Schizophrenia Bulletin Open</i> , <b>2020</b> , 1,	2.2	1
213	The Role of Glucagon in the Acute Therapeutic Effects of SGLT2 Inhibition. <i>Diabetes</i> , <b>2020</b> , 69, 2619-2629.	9.9	5
212	Circulating Levels of the Soluble Receptor for AGE (sRAGE) during Escalating Oral Glucose Dosages and Corresponding Isoglycaemic i.v. Glucose Infusions in Individuals with and without Type 2 Diabetes. <i>Nutrients</i> , <b>2020</b> , 12,	6.7	1
211	One Year $\beta$ Treatment with the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Decreases Hepatic Fat Content in Women with Nonalcoholic Fatty Liver Disease and Prior Gestational Diabetes Mellitus in a Randomized, Placebo-Controlled Trial. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	2
210	Normal insulin sensitivity, glucose tolerance, gut incretin and pancreatic hormone responses in adults with atopic dermatitis. <i>Diabetes, Obesity and Metabolism</i> , <b>2020</b> , 22, 2161-2169	6.7	0
209	Efficacy and Safety of Glimepiride With or Without Linagliptin Treatment in Patients With HNF1A Diabetes (Maturity-Onset Diabetes of the Young Type 3): A Randomized, Double-Blinded, Placebo-Controlled, Crossover Trial (GLIMLINA). <i>Diabetes Care</i> , <b>2020</b> , 43, 2025-2033	14.6	10
208	The role of endogenous GIP and GLP-1 in postprandial bone homeostasis. <i>Bone</i> , <b>2020</b> , 140, 115553	4.7	10
207	Glucose-Dependent Insulinotropic Polypeptide (GIP) Reduces Bone Resorption in Patients With Type 2 Diabetes. <i>Journal of the Endocrine Society</i> , <b>2020</b> , 4, bvaa097	0.4	3
206	Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1-7 randomised controlled trials. <i>Lancet Diabetes and Endocrinology</i> , <b>2020</b> , 8, 880-893	18.1	27
205	Survival of patients with and without diabetes following out-of-hospital cardiac arrest: A nationwide Danish study. <i>European Heart Journal: Acute Cardiovascular Care</i> , <b>2020</b> , 9, 599-607	4.3	3
204	Changes in oxidative nucleic acid modifications and inflammation following one-week treatment with the bile acid sequestrant sevelamer: Two randomised, placebo-controlled trials. <i>Journal of Diabetes and Its Complications</i> , <b>2020</b> , 34, 107446	3.2	3

203	Amylin and Calcitonin: Potential Therapeutic Strategies to Reduce Body Weight and Liver Fat. <i>Frontiers in Endocrinology</i> , <b>2020</b> , 11, 617400	5.7	15
202	The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretion-A Review. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3	23
201	Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study. <i>Diabetologia</i> , <b>2019</b> , 62, 665-675	10.3	51
200	Dapagliflozin Plus Saxagliptin Add-on Therapy Compared With Insulin in Patients With Type 2 Diabetes Poorly Controlled by Metformin With or Without Sulfonylurea Therapy: A Randomized Clinical Trial. <i>Diabetes Care</i> , <b>2019</b> , 42, 1464-1472	14.6	4
199	Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. <i>New England Journal of Medicine</i> , <b>2019</b> , 381, 841-851	59.2	567
198	An echocardiographic substrate for dyspnea identifies high risk patients with type 2 diabetes. <i>International Journal of Cardiology</i> , <b>2019</b> , 289, 119-124	3.2	2
197	Plasma proteome profiling discovers novel proteins associated with non-alcoholic fatty liver disease. <i>Molecular Systems Biology</i> , <b>2019</b> , 15, e8793	12.2	94
196	Separate and Combined Effects of GIP and GLP-1 Infusions on Bone Metabolism in Overweight Men Without Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2019</b> , 104, 2953-2960	5.6	26
195	Fixed-ratio combination of insulin degludec and liraglutide (IDegLira) improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 1506-1512	6.7	11
194	The efficacy and safety of exenatide once weekly in patients with type 2 diabetes. <i>Expert Opinion on Pharmacotherapy</i> , <b>2019</b> , 20, 501-510	4	9
193	Investigating Intestinal Glucagon After Roux-en-Y Gastric Bypass Surgery. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2019</b> , 104, 6403-6416	5.6	21
192	Gluco-metabolic effects of oral and intravenous alcohol administration in men. <i>Endocrine Connections</i> , <b>2019</b> , 8, 1372-1382	3.5	4
191	64-OR: Postprandial Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide in Type 2 Diabetes. <i>Diabetes</i> , <b>2019</b> , 68, 64-OR	0.9	10
190	1186-P: Lean Women with Polycystic Ovary Syndrome and Insulin Resistance Have Normal Incretin Effect, which Is Unaffected by Metformin Therapy. <i>Diabetes</i> , <b>2019</b> , 68, 1186-P	0.9	
189	Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: A systematic review and individual participant data meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 293-302	6.7	40
188	Prevalence of heart failure and the diagnostic value of MR-proANP in outpatients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 736-740	6.7	9
187	Management of people with Type 2 diabetes shared between a specialized outpatient clinic and primary health care is noninferior to management in a specialized outpatient clinic: a randomized, noninferiority trial. <i>Diabetic Medicine</i> , <b>2019</b> , 36, 854-861	3.5	3
186	High prevalence of prediabetes and metabolic abnormalities in overweight or obese schizophrenia patients treated with clozapine or olanzapine. <i>CNS Spectrums</i> , <b>2019</b> , 24, 441-452	1.8	8

185	Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals. <i>American Journal of Physiology - Renal Physiology</i> , <b>2019</b> , 316, G462-G472	5.1	63
184	Separate and Combined Glucometabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide 1 in Healthy Individuals. <i>Diabetes</i> , <b>2019</b> , 68, 906-917	0.9	70
183	Dietary habits and adherence to dietary recommendations in patients with type 1 and type 2 diabetes compared with the general population in Denmark. <i>Nutrition</i> , <b>2019</b> , 61, 49-55	4.8	15
182	One-year follow-up on liraglutide treatment for prediabetes and overweight/obesity in clozapine- or olanzapine-treated patients. <i>Acta Psychiatrica Scandinavica</i> , <b>2019</b> , 139, 26-36	6.5	19
181	Glucose metabolism in patients with psoriasis. <i>British Journal of Dermatology</i> , <b>2019</b> , 180, 264-271	4	7
180	Patient Assessment of Family Function, Glycemic Control and Quality of Life in Adult Patients With Type 2 Diabetes and Incipient Complications. <i>Canadian Journal of Diabetes</i> , <b>2019</b> , 43, 193-200	2.1	8
179	Glucose-lowering effects and mechanisms of the bile acid-sequestering resin sevelamer. <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 1623-1631	6.7	11
178	Is glucagon-like peptide-1 fully protected by the dipeptidyl peptidase 4 inhibitor sitagliptin when administered to patients with type 2 diabetes?. <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 1937-1943	6.7	3
177	FGF21, a liver hormone that inhibits alcohol intake in mice, increases in human circulation after acute alcohol ingestion and sustained binge drinking at Oktoberfest. <i>Molecular Metabolism</i> , <b>2018</b> , 11, 96-103	8.8	34
176	Ghrelin secretion in humans - a role for the vagus nerve?. <i>Neurogastroenterology and Motility</i> , <b>2018</b> , 30, e13295	4	13
175	Glucose-Dependent Insulinotropic Polypeptide (GIP) Inhibits Bone Resorption Independently of Insulin and Glycemia. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2018</b> , 103, 288-294	5.6	46
174	Neuroprotective Mechanisms of Glucagon-like Peptide-1-based Therapies in Ischaemic Stroke: A Systematic Review based on Pre-Clinical Studies. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>2018</b> , 122, 559-569	3.1	25
173	Cardiovascular biomarkers in clinical studies of type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 1350-1360	6.7	13
172	The Role of Glucagon in the Pathophysiology and Treatment of Type 2 Diabetes. <i>Mayo Clinic Proceedings</i> , <b>2018</b> , 93, 217-239	6.4	57
171	Guanylin and uroguanylin mRNA expression is increased following Roux-en-Y gastric bypass, but guanylins do not play a significant role in body weight regulation and glycemic control. <i>Peptides</i> , <b>2018</b> , 101, 32-43	3.8	9
170	Glucagon-like peptide 1 in health and disease. <i>Nature Reviews Endocrinology</i> , <b>2018</b> , 14, 390-403	15.2	187
169	Effects of Smoking Versus Nonsmoking on Postprandial Glucose Metabolism in Heavy Smokers Compared With Nonsmokers. <i>Diabetes Care</i> , <b>2018</b> , 41, 1260-1267	14.6	7
168	Presence of micro- and macroalbuminuria and the association with cardiac mechanics in patients with type 2 diabetes. <i>European Heart Journal Cardiovascular Imaging</i> , <b>2018</b> , 19, 1034-1041	4.1	16

167	GIP(3-30)NH is an efficacious GIP receptor antagonist in humans: a randomised, double-blinded, placebo-controlled, crossover study. <i>Diabetologia</i> , <b>2018</b> , 61, 413-423	10.3	52
166	Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk factors: A narrative review of head-to-head comparisons. <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 508-519	6.7	25
165	Hyperglucagonemia correlates with plasma levels of non-branched-chain amino acids in patients with liver disease independent of type 2 diabetes. <i>American Journal of Physiology - Renal Physiology</i> , <b>2018</b> , 314, G91-G96	5.1	29
164	Enteroendocrine K and L cells in healthy and type 2 diabetic individuals. <i>Diabetologia</i> , <b>2018</b> , 61, 284-294	10.3	66
163	Protocol for Meal-time Administration of Exenatide for Glycaemic Control in Type 1 Diabetes Cases (The MAG1C trial): a randomised, double-blinded, placebo-controlled trial. <i>BMJ Open</i> , <b>2018</b> , 8, e021861	3	2
162	Does glucagon-like peptide-1 (GLP-1) receptor agonist stimulation reduce alcohol intake in patients with alcohol dependence: study protocol of a randomised, double-blinded, placebo-controlled clinical trial. <i>BMJ Open</i> , <b>2018</b> , 8, e019562	3	16
161	Model-Based Prediction of Plasma Concentration and Enterohepatic Circulation of Total Bile Acids in Humans. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , <b>2018</b> , 7, 603-612	4.5	9
160	Effects of liraglutide on gallbladder emptying: A randomized, placebo-controlled trial in adults with overweight or obesity. <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 2557-2564	6.7	15
159	Metformin-induced glucagon-like peptide-1 secretion contributes to the actions of metformin in type 2 diabetes. <i>JCI Insight</i> , <b>2018</b> , 3,	9.9	44
158	Semaglutide Treatment and Renal Function in the SUSTAIN 6 Trial. <i>Diabetes</i> , <b>2018</b> , 67, 1084-P	0.9	5
157	Dapagliflozin plus Saxagliptin Shows Noninferior A1C Reduction vs. Insulin Glargine in Patients with Type 2 Diabetes Inadequately Controlled by Metformin With or Without Sulfonylurea. <i>Diabetes</i> , <b>2018</b> , 67, 260-OR	0.9	
156	Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 889-897	6.7	114
155	The bile acid-sequestering resin sevelamer eliminates the acute GLP-1 stimulatory effect of endogenously released bile acids in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 362-369	6.7	26
154	Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD. <i>Frontiers in Endocrinology</i> , <b>2018</b> , 9, 649	5.7	43
153	Glimepiride monotherapy versus combination of glimepiride and linagliptin therapy in patients with HNF1A-diabetes: a protocol for a randomised, double-blinded, placebo-controlled trial. <i>BMJ Open</i> , <b>2018</b> , 8, e022517	3	5
152	Determinants of Fasting Hyperglucagonemia in Patients with Type 2 Diabetes and Nondiabetic Control Subjects. <i>Metabolic Syndrome and Related Disorders</i> , <b>2018</b> , 16, 530-536	2.6	10
151	Semaglutide Treatment and Renal Function in the SUSTAIN 6 Trial. <i>Canadian Journal of Diabetes</i> , <b>2018</b> , 42, S42	2.1	14
150	Recovery of gut microbiota of healthy adults following antibiotic exposure. <i>Nature Microbiology</i> , <b>2018</b> , 3, 1255-1265	26.6	246



149	No changes in levels of bone formation and resorption markers following a broad-spectrum antibiotic course. <i>BMC Endocrine Disorders</i> , <b>2018</b> , 18, 60	3.3	3
148	Bone Turnover Markers in Patients With Nonalcoholic Fatty Liver Disease and/or Type 2 Diabetes During Oral Glucose and Isoglycemic Intravenous Glucose. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2018</b> , 103, 2042-2049	5.6	10
147	Cardiovascular safety and benefits of GLP-1 receptor agonists. <i>Expert Opinion on Drug Safety</i> , <b>2017</b> , 16, 351-363	4.1	25
146	Efficacy and safety of fixed-ratio combination of insulin degludec and liraglutide (IDegLira) for the treatment of type 2 diabetes. <i>Expert Opinion on Drug Safety</i> , <b>2017</b> , 16, 387-396	4.1	11
145	Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , <b>2017</b> , 19, 906-908	6.7	59
144	Exenatide: pharmacokinetics, clinical use, and future directions. <i>Expert Opinion on Pharmacotherapy</i> , <b>2017</b> , 18, 555-571	4	39
143	A Fixed Ratio Combination of Insulin Degludec and Liraglutide (IDegLira) Reduces Glycemic Fluctuation and Brings More Patients with Type 2 Diabetes Within Blood Glucose Target Ranges. <i>Diabetes Technology and Therapeutics</i> , <b>2017</b> , 19, 255-264	8.1	17
142	Bile acid sequestrants for glycemic control in patients with type 2 diabetes: A systematic review with meta-analysis of randomized controlled trials. <i>Journal of Diabetes and Its Complications</i> , <b>2017</b> , 31, 918-927	3.2	46
141	Effect of exercise combined with glucagon-like peptide-1 receptor agonist treatment on cardiac function: A randomized double-blind placebo-controlled clinical trial. <i>Diabetes, Obesity and Metabolism</i> , <b>2017</b> , 19, 1040-1044	6.7	18
140	The effect of empagliflozin on oxidative nucleic acid modifications in patients with type 2 diabetes: protocol for a randomised, double-blinded, placebo-controlled trial. <i>BMJ Open</i> , <b>2017</b> , 7, e014728	3	9
139	Therapy: Liraglutide - preventing or postponing T2DM diagnosis?. <i>Nature Reviews Endocrinology</i> , <b>2017</b> , 13, 320-322	15.2	1
138	A sandwich ELISA for measurement of the primary glucagon-like peptide-1 metabolite. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , <b>2017</b> , 313, E284-E291	6	8
137	Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder: A Randomized Clinical Trial. <i>JAMA Psychiatry</i> , <b>2017</b> , 74, 719-728	14.5	80
136	Women with prior gestational diabetes mellitus and prediabetes are characterised by a decreased incretin effect. <i>Diabetologia</i> , <b>2017</b> , 60, 1344-1353	10.3	9
135	Mathematical Modelling of Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide-1 following Ingestion of Glucose. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>2017</b> , 121, 290-297	3.1	2
134	Evidence connecting old, new and neglected glucose-lowering drugs to bile acid-induced GLP-1 secretion: A review. <i>Diabetes, Obesity and Metabolism</i> , <b>2017</b> , 19, 1214-1222	6.7	12
133	Current Therapies That Modify Glucagon Secretion: What Is the Therapeutic Effect of Such Modifications?. <i>Current Diabetes Reports</i> , <b>2017</b> , 17, 128	5.6	11
132	Liraglutide for the Treatment of Antipsychotic Drug-Induced Weight Gain-Reply. <i>JAMA Psychiatry</i> , <b>2017</b> , 74, 1173-1174	14.5	2

131	Supportive and non-supportive interactions in families with a type 2 diabetes patient: an integrative review. <i>Diabetology and Metabolic Syndrome</i> , <b>2017</b> , 9, 57	5.6	36
130	Single-Dose Metformin Enhances Bile Acid-Induced Glucagon-Like Peptide-1 Secretion in Patients With Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2017</b> , 102, 4153-4162	5.6	19
129	Circulating Glucagon 1-61 Regulates Blood Glucose by Increasing Insulin Secretion and Hepatic Glucose Production. <i>Cell Reports</i> , <b>2017</b> , 21, 1452-1460	10.6	18
128	Impaired beta cell sensitivity to incretins in type 2 diabetes is insufficiently compensated by higher incretin response. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , <b>2017</b> , 27, 1123-1129	4.5	12
127	Nonalcoholic Fatty Liver Disease Is Prevalent in Women With Prior Gestational Diabetes Mellitus and Independently Associated With Insulin Resistance and Waist Circumference. <i>Diabetes Care</i> , <b>2017</b> , 40, 109-116	14.6	33
126	Use of antibiotics in childhood and risk of Type 1 diabetes: a population-based case-control study. <i>Diabetic Medicine</i> , <b>2017</b> , 34, 272-277	3.5	25
125	The impact of EndoBarrier gastrointestinal liner in obese patients with normal glucose tolerance and in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , <b>2017</b> , 19, 189-199	6.7	15
124	Near-normalization of glycaemic control with glucagon-like peptide-1 receptor agonist treatment combined with exercise in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , <b>2017</b> , 19, 172-180	6.7	21
123	Metformin-associated risk of acute dialysis in patients with type 2 diabetes: A nationwide cohort study. <i>Diabetes, Obesity and Metabolism</i> , <b>2016</b> , 18, 1283-1287	6.7	10
122	Higher Endogenous Glucose Production During OGTT vs Isoglycemic Intravenous Glucose Infusion. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2016</b> , 101, 4377-4384	5.6	8
121	Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, 1834-1844	59.2	2547
120	Impact of type 2 diabetes and duration of type 2 diabetes on cardiac structure and function. <i>International Journal of Cardiology</i> , <b>2016</b> , 221, 114-21	3.2	24
119	Mechanism-Based Modeling of Gastric Emptying Rate and Gallbladder Emptying in Response to Caloric Intake. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , <b>2016</b> , 5, 692-700	4.5	9
118	Disturbed postprandial glucose metabolism and gut hormone responses in non-diabetic patients with psoriasis. <i>British Journal of Dermatology</i> , <b>2016</b> , 175, 1085-1088	4	3
117	Type 2 Diabetes Patients Reach Target Glycemic Control Faster Using IDegLira than Either Insulin Degludec or Liraglutide Given Alone. <i>Clinical Drug Investigation</i> , <b>2016</b> , 36, 293-303	3.2	11
116	Cholecystokinin-Induced Gallbladder Emptying and Metformin Elicit Additive Glucagon-Like Peptide-1 Responses. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2016</b> , 101, 2076-83	5.6	20
115	Postprandial Plasma Concentrations of Individual Bile Acids and FGF-19 in Patients With Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2016</b> , 101, 3002-9	5.6	72
114	Abnormal echocardiography in patients with type 2 diabetes and relation to symptoms and clinical characteristics. <i>Diabetes and Vascular Disease Research</i> , <b>2016</b> , 13, 321-30	3.3	28

113	Risk stratification by endocrinologists of patients with type 2 diabetes in a Danish specialised outpatient clinic: a cross-sectional study. <i>BMC Health Services Research</i> , <b>2016</b> , 16, 124	2.9	10
112	Shared care management of patients with type 2 diabetes across the primary and secondary healthcare sectors: study protocol for a randomised controlled trial. <i>Trials</i> , <b>2016</b> , 17, 277	2.8	7
111	Effect of chenodeoxycholic acid and the bile acid sequestrant colesevelam on glucagon-like peptide-1 secretion. <i>Diabetes, Obesity and Metabolism</i> , <b>2016</b> , 18, 571-80	6.7	55
110	Evidence of Extrapancreatic Glucagon Secretion in Man. <i>Diabetes</i> , <b>2016</b> , 65, 585-97	0.9	102
109	Cephalic phase secretion of insulin and other enteropancreatic hormones in humans. <i>American Journal of Physiology - Renal Physiology</i> , <b>2016</b> , 310, G43-51	5.1	38
108	GLP-1 and Amylin in the Treatment of Obesity. <i>Current Diabetes Reports</i> , <b>2016</b> , 16, 1	5.6	35
107	Effects of glucagon-like peptide-1 on glucagon secretion in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , <b>2016</b> , 64, 908-15	13.4	15
106	Trends in One-Year Outcomes of Dialysis-Requiring Acute Kidney Injury in Denmark 2005-2012: A Population-Based Nationwide Study. <i>PLoS ONE</i> , <b>2016</b> , 11, e0159944	3.7	13
105	Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , <b>2016</b> , 11, e0166125	3.7	126
104	Dialysis-Requiring Acute Kidney Injury in Denmark 2000-2012: Time Trends of Incidence and Prevalence of Risk Factors-A Nationwide Study. <i>PLoS ONE</i> , <b>2016</b> , 11, e0148809	3.7	23
103	Effect of the EndoBarrier Gastrointestinal Liner on obesity and type 2 diabetes: a systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , <b>2016</b> , 18, 300-5	6.7	83
102	Involvement of glucagon-like peptide-1 in the glucose-lowering effect of metformin. <i>Diabetes, Obesity and Metabolism</i> , <b>2016</b> , 18, 955-61	6.7	42
101	Semimechanistic model describing gastric emptying and glucose absorption in healthy subjects and patients with type 2 diabetes. <i>Journal of Clinical Pharmacology</i> , <b>2016</b> , 56, 340-8	2.9	8
100	Diabetic Ketoacidosis in a Patient with Type 2 Diabetes After Initiation of Sodium-Glucose Cotransporter 2 Inhibitor Treatment. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>2016</b> , 118, 168-70	3.1	32
99	Diabetic and nondiabetic patients with nonalcoholic fatty liver disease have an impaired incretin effect and fasting hyperglucagonaemia. <i>Journal of Internal Medicine</i> , <b>2016</b> , 279, 485-93	10.8	32
98	Non-Insulin Parenteral Therapies <b>2016</b> , 455-470		
97	Alcohol consumption among patients with diabetes: a survey-based cross-sectional study of Danish adults with diabetes. <i>Scandinavian Journal of Public Health</i> , <b>2016</b> , 44, 517-24	3	9
96	Oxyntomodulin Identified as a Marker of Type 2 Diabetes and Gastric Bypass Surgery by Mass-spectrometry Based Profiling of Human Plasma. <i>EBioMedicine</i> , <b>2016</b> , 7, 112-20	8.8	42

95	Involvement of steatosis-induced glucagon resistance in hyperglucagonaemia. <i>Medical Hypotheses</i> , <b>2016</b> , 86, 100-3	3.8	17
94	Glucagon-like peptide-1 (GLP-1) analogues: A potential new treatment for alcohol use disorder?. <i>Nordic Journal of Psychiatry</i> , <b>2016</b> , 70, 561-2	2.3	4
93	Cholesterol remnants and triglycerides are associated with decreased myocardial function in patients with type 2 diabetes. <i>Cardiovascular Diabetology</i> , <b>2016</b> , 15, 137	8.7	14
92	Benefits of combination of insulin degludec and liraglutide are independent of baseline glycated haemoglobin level and duration of type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , <b>2016</b> , 18, 40-8	6.7	26
91	Lack of effect of the glucagon-like peptide-1 receptor agonist liraglutide on psoriasis in glucose-tolerant patients--a randomized placebo-controlled trial. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2015</b> , 29, 555-9	4.6	23
90	Plasma YKL-40 during pregnancy and gestational diabetes mellitus. <i>Journal of Reproductive Immunology</i> , <b>2015</b> , 112, 68-72	4.2	5
89	Pancreatic polypeptide responses to isoglycemic oral and intravenous glucose in humans with and without intact vagal innervation. <i>Peptides</i> , <b>2015</b> , 71, 229-31	3.8	12
88	Adverse drug reactions associated with the use of liraglutide in patients with type 2 diabetes--focus on pancreatitis and pancreas cancer. <i>Expert Opinion on Drug Safety</i> , <b>2015</b> , 14, 171-80	4.1	23
87	Effect of Roux-en-Y gastric bypass on the distribution and hormone expression of small-intestinal enteroendocrine cells in obese patients with type 2 diabetes. <i>Diabetologia</i> , <b>2015</b> , 58, 2254-8	10.3	83
86	Pancreatic Amylase and Lipase Plasma Concentrations Are Unaffected by Increments in Endogenous GLP-1 Levels Following Liquid Meal Tests. <i>Diabetes Care</i> , <b>2015</b> , 38, e71-2	14.6	10
85	Postprandial incretin and islet hormone responses and dipeptidyl-peptidase 4 enzymatic activity in patients with maturity onset diabetes of the young. <i>European Journal of Endocrinology</i> , <b>2015</b> , 173, 205-15	6.5	10
84	Fixed combination of insulin and a glucagon-like peptide-1 analog for the treatment of type 2 diabetes, exemplified by insulin degludec and liraglutide. <i>Expert Review of Clinical Pharmacology</i> , <b>2015</b> , 8, 273-82	3.8	1
83	Premature explantation of an EndoBarrier gastrointestinal liner because of sleeve invagination. <i>Endoscopy</i> , <b>2015</b> , 47 Suppl 1 UCTN, E275-6	3.4	3
82	Effect of Oxyntomodulin, Glucagon, GLP-1, and Combined Glucagon +GLP-1 Infusion on Food Intake, Appetite, and Resting Energy Expenditure. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2015</b> , 100, 4541-52	5.6	51
81	Transfer of liraglutide from blood to cerebrospinal fluid is minimal in patients with type 2 diabetes. <i>International Journal of Obesity</i> , <b>2015</b> , 39, 1651-4	5.5	33
80	Glucose-dependent insulinotropic polypeptide augments glucagon responses to hypoglycemia in type 1 diabetes. <i>Diabetes</i> , <b>2015</b> , 64, 72-8	0.9	49
79	Retinal vascular and structural dynamics during acute hyperglycaemia. <i>Acta Ophthalmologica</i> , <b>2015</b> , 93, 697-705	3.7	7
78	Impaired incretin effect is an early sign of glucose dysmetabolism in nondiabetic patients with psoriasis. <i>Journal of Internal Medicine</i> , <b>2015</b> , 278, 660-70	10.8	13

77	Influence of gastrointestinal factors on glucose metabolism in patients with cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2015</b> , 30, 1522-8	4	10
76	Effect of Antibiotics on Gut Microbiota, Gut Hormones and Glucose Metabolism. <i>PLoS ONE</i> , <b>2015</b> , 10, e0142352	3.7	61
75	The role of efferent cholinergic transmission for the insulinotropic and glucagonostatic effects of GLP-1. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , <b>2015</b> , 309, R544-51	3.2	19
74	IDegLira Versus Alternative Intensification Strategies in Patients with Type 2 Diabetes Inadequately Controlled on Basal Insulin Therapy. <i>Diabetes Therapy</i> , <b>2015</b> , 6, 573-591	3.6	24
73	Patients with psoriasis are insulin resistant. <i>Journal of the American Academy of Dermatology</i> , <b>2015</b> , 72, 599-605	4.5	48
72	Sevelamer in a diabetologist's perspective: a phosphate-binding resin with glucose-lowering potential. <i>Diabetes, Obesity and Metabolism</i> , <b>2015</b> , 17, 116-20	6.7	10
71	Incretin effect and glucagon responses to oral and intravenous glucose in patients with maturity-onset diabetes of the young--type 2 and type 3. <i>Diabetes</i> , <b>2014</b> , 63, 2838-44	0.9	34
70	Glucose-dependent insulinotropic polypeptide: blood glucose stabilizing effects in patients with type 2 diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2014</b> , 99, E418-26	5.6	57
69	Glucagon and type 2 diabetes: the return of the alpha cell. <i>Current Diabetes Reports</i> , <b>2014</b> , 14, 555	5.6	71
68	Postprandial gallbladder emptying in patients with type 2 diabetes: potential implications for bile-induced secretion of glucagon-like peptide 1. <i>European Journal of Endocrinology</i> , <b>2014</b> , 171, 407-19	6.5	46
67	Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira). <i>Diabetes Care</i> , <b>2014</b> , 37, 2926-33	14.6	189
66	Glucagon responses to increasing oral loads of glucose and corresponding isoglycaemic intravenous glucose infusions in patients with type 2 diabetes and healthy individuals. <i>Diabetologia</i> , <b>2014</b> , 57, 1720-5	10.3	39
65	Hyperglucagonaemia analysed by glucagon sandwich ELISA: nonspecific interference or truly elevated levels?. <i>Diabetologia</i> , <b>2014</b> , 57, 1919-26	10.3	129
64	Unprecedented high insulin secretion in a healthy human subject after intravenous glucagon-like peptide-1: a case report. <i>BMC Research Notes</i> , <b>2014</b> , 7, 326	2.3	1
63	Glucose-lowering effects and low risk of hypoglycemia in patients with maturity-onset diabetes of the young when treated with a GLP-1 receptor agonist: a double-blind, randomized, crossover trial. <i>Diabetes Care</i> , <b>2014</b> , 37, 1797-805	14.6	56
62	Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities. <i>European Journal of Internal Medicine</i> , <b>2014</b> , 25, 407-14	3.9	101
61	A 25-year-old woman with type 2 diabetes and liver disease. <i>Case Reports in Gastroenterology</i> , <b>2014</b> , 8, 398-403	1	1
60	Glucose-dependent insulinotropic polypeptide inhibits bone resorption in humans. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2014</b> , 99, E2325-9	5.6	86

59	On the role of gallbladder emptying and incretin hormones for nutrient-mediated TSH suppression in patients with type 2 diabetes. <i>Endocrine Connections</i> , <b>2014</b> , 3, 193-9	3.5	2
58	Does a GLP-1 receptor agonist change glucose tolerance in patients treated with antipsychotic medications? Design of a randomised, double-blinded, placebo-controlled clinical trial. <i>BMJ Open</i> , <b>2014</b> , 4, e004227	3	13
57	The impact of dipeptidyl peptidase 4 inhibition on incretin effect, glucose tolerance, and gastrointestinal-mediated glucose disposal in healthy subjects. <i>European Journal of Endocrinology</i> , <b>2014</b> , 171, 353-62	6.5	19
56	Effects of lixisenatide on elevated liver transaminases: systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetes. <i>BMJ Open</i> , <b>2014</b> , 4, e005325	3	44
55	Specificity and sensitivity of commercially available assays for glucagon and oxyntomodulin measurement in humans. <i>European Journal of Endocrinology</i> , <b>2014</b> , 170, 529-38	6.5	101
54	Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies. <i>Diabetologia</i> , <b>2013</b> , 56, 965-72	10.3	167
53	Secretion of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes: systematic review and meta-analysis of clinical studies. <i>Diabetes Care</i> , <b>2013</b> , 36, 3346-52	14.6	101
52	Postpartum reversibility of impaired incretin effect in gestational diabetes mellitus. <i>Regulatory Peptides</i> , <b>2013</b> , 186, 104-7		13
51	The Role of Glucagon-like Receptor-1 Agonists in the Metabolic Syndrome <b>2013</b> , 165-183		
50	The effect of a glucagon-like peptide-1 receptor agonist on glucose tolerance in women with previous gestational diabetes mellitus: protocol for an investigator-initiated, randomised, placebo-controlled, double-blinded, parallel intervention trial. <i>BMJ Open</i> , <b>2013</b> , 3, e003834	3	7
49	Characterisation of oral and i.v. glucose handling in truncally vagotomised subjects with pyloroplasty. <i>European Journal of Endocrinology</i> , <b>2013</b> , 169, 187-201	6.5	42
48	Glucagon and the gut hormones GLP-1 and oxyntomodulin increase resting energy expenditure in man. <i>Regulatory Peptides</i> , <b>2012</b> , 177, S15-S16		2
47	Non-glycaemic effects mediated via GLP-1 receptor agonists and the potential for exploiting these for therapeutic benefit: focus on liraglutide. <i>Diabetes, Obesity and Metabolism</i> , <b>2012</b> , 14 Suppl 2, 41-9	6.7	20
46	Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. <i>BMJ, The</i> , <b>2012</b> , 344, d7771	5.9	575
45	The effect of glucagon-like peptide 1 on cardiovascular risk. <i>Nature Reviews Cardiology</i> , <b>2012</b> , 9, 209-22	14.8	117
44	Emerging GLP-1 receptor agonists. <i>Expert Opinion on Emerging Drugs</i> , <b>2011</b> , 16, 607-18	3.7	20
43	Glucagon antagonism as a potential therapeutic target in type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , <b>2011</b> , 13, 965-71	6.7	99
42	The GetGoal clinical trial program of lixisenatide, a once-daily GLP-1 receptor agonist. <i>Expert Review of Endocrinology and Metabolism</i> , <b>2011</b> , 6, 513-525	4.1	5

41	Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes. <i>Diabetes Care</i> , <b>2011</b> , 34 Suppl 2, S251-7	14.6	185
40	Increased postprandial GIP and glucagon responses, but unaltered GLP-1 response after intervention with steroid hormone, relative physical inactivity, and high-calorie diet in healthy subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2011</b> , 96, 447-53	5.6	124
39	Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans. <i>Diabetes</i> , <b>2011</b> , 60, 3103-9	0.9	208
38	Impaired regulation of the incretin effect in patients with type 2 diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2011</b> , 96, 737-45	5.6	157
37	The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , <b>2011</b> , 300, E1038-46	6	118
36	The alpha-cell as target for type 2 diabetes therapy. <i>Review of Diabetic Studies</i> , <b>2011</b> , 8, 369-81	3.6	42
35	Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , <b>2010</b> , 12, 167-77	6.7	262
34	The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action. <i>Diabetes</i> , <b>2010</b> , 59, 1765-70	0.9	194
33	Inappropriate glucagon response after oral compared with isoglycemic intravenous glucose administration in patients with type 1 diabetes. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , <b>2010</b> , 298, E832-7	6	53
32	Glucagon-like peptide-2, but not glucose-dependent insulinotropic polypeptide, stimulates glucagon release in patients with type 1 diabetes. <i>Regulatory Peptides</i> , <b>2010</b> , 163, 96-101		17
31	Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes - a review. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , <b>2010</b> , 3, 155-63	3.4	10
30	Incretin-based therapy of type 2 diabetes mellitus. <i>Current Protein and Peptide Science</i> , <b>2009</b> , 10, 46-55	2.8	37
29	Incretin-based therapies: viewpoints on the way to consensus. <i>Diabetes Care</i> , <b>2009</b> , 32 Suppl 2, S223-31	14.6	123
28	Preserved inhibitory potency of GLP-1 on glucagon secretion in type 2 diabetes mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2009</b> , 94, 4679-87	5.6	82
27	Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. <i>Diabetologia</i> , <b>2009</b> , 52, 199-207	10.3	296
26	The effects of glucagon-like peptide-1 on the beta cell. <i>Diabetes, Obesity and Metabolism</i> , <b>2009</b> , 11 Suppl 3, 11-8	6.7	85
25	The incretin system and its role in type 2 diabetes mellitus. <i>Molecular and Cellular Endocrinology</i> , <b>2009</b> , 297, 127-36	4.4	397
24	The spectrum of antidiabetic actions of GLP-1 in patients with diabetes. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , <b>2009</b> , 23, 453-62	6.5	19

23	Liraglutide: a human GLP-1 analog for Type 2 diabetes. <i>Therapy: Open Access in Clinical Medicine</i> , <b>2009</b> , 6, 199-207		6
22	Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus. <i>Diabetic Medicine</i> , <b>2008</b> , 25, 152-6	3.5	175
21	Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes. <i>Diabetic Medicine</i> , <b>2008</b> , 25, 1129-31	3.5	149
20	Glucagon-like peptide-1, glucose homeostasis and diabetes. <i>Trends in Molecular Medicine</i> , <b>2008</b> , 14, 161-8	1.5	128
19	Long-acting GLP-1 analogs for the treatment of type 2 diabetes mellitus. <i>BioDrugs</i> , <b>2008</b> , 22, 251-7	7.9	18
18	Initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin for patients with Type 2 diabetes mellitus. <i>Expert Review of Endocrinology and Metabolism</i> , <b>2008</b> , 3, 13-19	4.1	1
17	Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state?. <i>Diabetes</i> , <b>2007</b> , 56, 1951-9	0.9	251
16	Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. <i>Diabetes Care</i> , <b>2007</b> , 30, 1608-10	14.6	376
15	Review: DPP IV inhibitors - current evidence and future directions. <i>British Journal of Diabetes and Vascular Disease</i> , <b>2007</b> , 7, 69-74		11
14	The insulinotropic effect of GIP is impaired in patients with chronic pancreatitis and secondary diabetes mellitus as compared to patients with chronic pancreatitis and normal glucose tolerance. <i>Regulatory Peptides</i> , <b>2007</b> , 144, 123-30		46
13	Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus. <i>Expert Opinion on Investigational Drugs</i> , <b>2007</b> , 16, 231-7	5.9	77
12	The elimination rates of intact GIP as well as its primary metabolite, GIP 3-42, are similar in type 2 diabetic patients and healthy subjects. <i>Regulatory Peptides</i> , <b>2006</b> , 137, 168-72		48
11	Incretins, insulin secretion and Type 2 diabetes mellitus. <i>Diabetologia</i> , <b>2004</b> , 47, 357-366	10.3	331
10	On the role of the incretin hormones GIP and GLP-1 in the pathogenesis of Type 2 diabetes mellitus. <i>Danish Medical Bulletin</i> , <b>2004</b> , 51, 364-70		13
9	Role of gastrointestinal hormones in postprandial reduction of bone resorption. <i>Journal of Bone and Mineral Research</i> , <b>2003</b> , 18, 2180-9	6.3	233
8	Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. <i>Regulatory Peptides</i> , <b>2003</b> , 114, 115-21		315
7	The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2003</b> , 88, 4897-903	5.6	175
6	Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2003</b> , 88, 2706-13	5.6	397



5	Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2003</b> , 88, 220-4	5.6	338
4	Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients. <i>Diabetologia</i> , <b>2002</b> , 45, 1111-9	10.3	400
3	No reactive hypoglycaemia in Type 2 diabetic patients after subcutaneous administration of GLP-1 and intravenous glucose. <i>Diabetic Medicine</i> , <b>2001</b> , 18, 144-9	3.5	56
2	Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. <i>Diabetes</i> , <b>2001</b> , 50, 609-13	0.9	747
1	Evaluation of beta-cell secretory capacity using glucagon-like peptide 1. <i>Diabetes Care</i> , <b>2000</b> , 23, 807-12	14.6	36